CP and COVID-19: The ranking for the ACM of severe COVID-19 patients from high to low was as follows: ALA (SUCRA: 83.0%), IG (SUCRA: 80.7%), ruxolitinib (SUCRA: 79.8%), mavrilimumab (SUCRA: 72.6%), lenzilumab (SUCRA: 55.3%), hydrocortisone (SUCRA: 53.8%), CP (SUCRA: 41.6%), mycobacterium-w (SUCRA: 40.8%), N-acetylcysteine (SUCRA: 32.4%), placebo (SUCRA: 31.3%), tocilizumab (SUCRA: 30.8%), LS (SUCRA: 28.6%), and HS (SUCRA: 19.1%) (Supplementary Figure 4).